Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21586586 | 1.00 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL529784 | 0.79 | KDM4E (0.37) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL10680048 | 0.77 | TSHR (0.40) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL21402602 | 0.76 | KDM4E (0.34) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL20354119 | 0.76 | KDM4E (0.34) | TP53KDM4E | |
| SCHEMBL5820006 | 0.74 | TSHR (0.42) | KDM4EEPHX1ALDH1A1 | |
| SCHEMBL10683117 | 0.74 | NAAA (0.37) | TP53KDM4ESMN1; SMN2EPHX1 | |
| SCHEMBL12826259 | 0.73 | EPHX1 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL20402494 | 0.73 | EPHX1 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL6769884 | 0.72 | CA1 (0.37) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, NT5C, DUT | TP53 831/4885KDM4E 3382/4885GMNN 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.